Study to assess pharmacokinetic, pharmacodynamic, safety and immunogenicity of a new adalimumab formulation in subjects with active rheumatoid arthritis. [Studie hodnotící farmakokinetiku, farmakodynamiku, bezpecnost a imunogenicitu noveho pripravku obsahujiciho adalimumab u subjektu s aktivni revmatoidni artritidou].

Trial Profile

Study to assess pharmacokinetic, pharmacodynamic, safety and immunogenicity of a new adalimumab formulation in subjects with active rheumatoid arthritis. [Studie hodnotící farmakokinetiku, farmakodynamiku, bezpecnost a imunogenicitu noveho pripravku obsahujiciho adalimumab u subjektu s aktivni revmatoidni artritidou].

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 16 Jun 2018 Results of pooled analysis (DE009, DE011, DE019, M10-261 and M13-390) presented at the 19th Annual Congress of the European League Against Rheumatism
    • 04 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top